• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus
【24h】

Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus

机译：上颌窦技术上不可切除的局部晚期癌的诱导化疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Locally advanced carcinoma of maxillary sinus has been historically reported to have poor prognosis. We evaluated the role of NACT in improving the outcome in these patients.Methods. 41 patients with locally advanced technically unresectable (stage IVa) or unresectable maxillary carcinoma (stage IVb) were treated with induction chemotherapy between 2008 and 2011. The demographic profile, response and toxicity of chemotherapy, definitive treatment received, progression free survival (PFS), and overall survival (OS) were analyzed. Univariate and multivariate analysis were performed to determine factors associated with PFS and OS.Results. The chemotherapy included two drugs (platinum and taxane) in 34 patients (82.9%) and three drugs (platinum, taxane, and 5 FU) in 7 (17.1%). There was no complete response seen in any of the patients, stable disease in 18 (43.9%), partial response in 16 (39%), and progression in 7 (17.1%) patients. After induction, the treatment planned included surgery in 12 (29.3%), CT-RT in 24 (58.5%), radical RT in 1 (2.4%), palliative RT in 1 (2.4%), and palliative chemotherapy in 3 (7.3%) patients. Overall, the median PFS was 10.0 months. The OS at 24 months and 36 months was 41% and 35%, respectively.Conclusion. In unresectable maxillary carcinoma, induction chemotherapy has clinically significant benefit with acceptable toxicity.
机译：背景。据报道，上颌窦局部晚期癌的预后较差。我们评估了NACT在改善这些患者预后中的作用。在2008年至2011年之间，对41例局部晚期无法手术切除的上级技术性癌症（IVa期）或无法手术切除的上颌癌（IVb期）的患者进行了人口统计学分析，化疗的反应和毒性，明确治疗，无进展生存期（PFS），分析了总生存期（OS）。进行单因素和多因素分析以确定与PFS和OS相关的因素。化疗包括34例患者（82.9％）中的两种药物（铂和紫杉烷）和7例患者（17.1％）中的三种药物（铂，紫杉烷和5 FU）。在所有患者中均未观察到完全缓解，在18名患者中病情稳定（43.9％），在16名患者中有部分缓解（39％），在7名患者中进展（17.1％）。诱导后，治疗计划包括手术治疗12例（29.3％），CT-RT治疗24例（58.5％），根治性RT疗法1例（2.4％），姑息性RT疗法1例（2.4％）和姑息性化疗3例（7.3） ％） 耐心。总体而言，PFS中位数为10.0个月。在24个月和36个月时的OS分别为41％和35％。在不可切除的上颌癌中，诱导化疗具有可接受的毒性，在临床上具有明显的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号